market trends

Jan 22, 2025

Acute Myeloid Leukemia (AML) represents a significant public health concern globally, with its prevalence and incidence on the rise. According to the American Cancer Society’s estimates for 2025, approximately 22K people in the United States are expected to be diagnosed with AML, with most cases occurring in adults...

Oct 02, 2024

Rheumatoid arthritis is a chronic autoimmune disease that wreaks havoc on the joints, causing progressive and destructive polyarthritis. According to the World Health Organization, approximately 18 million people globally live with this condition, with about 1.5 million cases reported in the U.S. Characterized by r...

Sep 04, 2024

Nonalcoholic Steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by liver inflammation and damage due to fat accumulation in the liver. Unlike simple fatty liver, NASH can progress to more serious conditions such as fibrosis, cirrhosis, and even liver failure. This chr...

Aug 18, 2024

"Research is the only hope for families affected by Duchenne muscular dystrophy, and every step forward is a step closer to a cure." Duchenne Muscular Dystrophy (DMD) is a severe form of muscular dystrophy characterized by progressive muscle degeneration and weakness. It is a rare disorder, but it is one of th...

Nov 10, 2017

Takeda and Portal Instruments partner to bring about needle-free form of drug delivery Takeda Pharmaceutical and Portal Instruments have partnered with a deal worth $100 million to develop a needle-free drug delivery device and increase patient compliance rates for biologic medicines manufactured by the former compa...

Oct 10, 2017

Novo petitions FDA to require copies of Victoza to conduct clinical trials With one drugmaker already trying to pry patent protection off of Novo Nordisk’s blockbuster Victoza before its 2022 expiration, the insulin specialist has taken new steps to deter copies. The Danish drugmaker has filed a citizen petition arg...

Jul 25, 2017

Samsung and Merck launch Remicade biosim at 35% discount After the first biosimilar of Johnson & Johnson’s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with a much deeper pricing slash. Samsung and marketing partner Merck & Co. Monday launched the...

Mar 07, 2017

NPPA slams pharma giants for overcharging The price regulator in the pharmaceutical industry, National Pharmaceutical Price Authority (NPPA) has discovered that the leading Pharma companies are overcharging customers for abundantly prevalent drugs in the market. NPPA has alleged that the listed 634 drugs are being s...

May 31, 2016

The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020. DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Antico...

May 12, 2016

Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa. DelveInsight Atrial Fibrillation-Market Insights & Drugs ...